Background and Purpose-Observational studies have reported increased risk of ischemic stroke among individuals with low serum 25-hydroxyvitamin D (S-25OHD) concentrations but uncertainty remains about the causality of this association. We sought to determine whether S-25OHD concentrations are causally associated with ischemic stroke and its subtypes using Mendelian randomization. Methods-We used summary-level data for ischemic stroke (34 217 cases and 404 630 noncases) from the MEGASTROKE consortium. As instruments, we used 6 single nucleotide polymorphisms, explaining 7.5% of the variance in S-25OHD, previously identified to be associated with S-25OHD concentrations in the Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits consortium (n=79 366). The analyses were conducted using the inverse-varianceweighted method and complemented with the weighted median, heterogeneity-penalized, and Mendelian randomizationEgger approaches.
O bservational studies have found that low concentrations of serum 25-hydroxyvitamin D (S-25OHD), the principal biomarker of vitamin D status, are associated with an increased risk of stroke. 1 A meta-analysis of 19 observational studies showed a 62% increased risk of stroke among individuals in the lowest versus highest categories of S-25OHD concentrations. 1 Randomized controlled trials have, however, failed to demonstrate a protective effect of vitamin D supplementation on stroke risk [2] [3] [4] but were generally underpowered to detect an association, had short follow-up, and some had poor compliance. Furthermore, the trials did not evaluate whether the impact of vitamin D varied by subtypes of ischemic stroke, which is a heterogeneous disease and subtypes have distinct pathogeneses and disease pathophysiology. 5 Mendelian randomization (MR) is an epidemiological study design that uses genetic variants, usually single-nucleotide polymorphisms (SNPs), with an impact on the modifiable (nongenetic) exposure of interest as proxy measures for the exposure to infer causality. 6 In 2 previous MR studies, a genetic risk score comprising SNPs in genes involved in 25OHD synthesis or substrate availability (CYP2R1 and DHCR7) was inversely associated with blood pressure 7, 8 but not with risk of ischemic stroke. 7 Another MR study found that a genetic variant in the vitamin D-binding protein was significantly associated with self-reported stroke and transient ischemic attacks in a cohort of 2122 adults (n=161 cases) but was not associated with ischemic stroke in a larger sample, including 12 389 cases and 62 004 controls.
Whether S-25OHD concentration is associated with any specific ischemic stroke subtype is unknown.
Using 6 SNPs explaining 7.5% of the variance in S-25OHD concentrations, we applied a 2-sample MR approach to determine the causal nature of the association of S-25OHD concentrations with ischemic stroke and to elucidate whether there are subtype-specific associations.
Methods

SNP Selection and Data Sources
We used summary-level data from the Study of Underlying Genetic Determinants of Vitamin D and Highly Related Traits (SUNLIGHT) 10 and MEGASTROKE 5 consortia. As instruments, we used the 6 independent SNPs associated with S-25OHD concentrations at genome-wide significance (P<5×10 -8 ) in up to 79 366 individuals of European ancestry in the SUNLIGHT consortium. 10 There was no evidence of population stratification or cryptic relatedness for the S-25OHD results. 10 From the MEGASTROKE consortium, 5 we extracted summary-level data for ischemic stroke from European-descent individuals only (to reduce potential bias from population stratification), including up to 404 630 noncases and 34 217 ischemic stroke cases. Cases were defined based on clinical and imaging criteria and subdivided into large artery stroke (n=4373), small vessel stroke (n=5386), and cardioembolic stroke (n=7193). Stroke subtyping was primarily based on the Trial of ORG 10172 in Acute Stroke Treatment criteria. Study-specific stroke ascertainment has been described elsewhere. 5 Studies participating in the SUNLIGHT and MEGASTROKE consortia received ethics approval from an institutional review board, and all participants provided informed consent. According to the Transparency and Openness Promotion Guidelines, the data and analytic methods used have been cited, and the data used for the analyses are available in Table I in the online-only Data Supplement.
Statistical Analysis
Analyses were performed using the conventional inverse-variance-weighted method (primary analysis) and complemented with the weighted median, heterogeneity-penalized, and MR-Egger approaches. 11, 12 Odds ratios (ORs) were scaled per 1-SD increase in ln-transformed S-25OHD concentrations. The SD (0.33 lnnmol/L; 1 SD on the normal scale corresponds to ≈18 nmol/L) was derived from the population-based Swedish Mammography Cohort. 13 The statistical analyses were conducted in Stata and R. Statistical power was estimated using the method proposed by Brion et al. 14 
Results
Associations of the S-25OHD-associated SNPs with ischemic stroke and its subtypes are shown in Table I Figures 1 and 2) . The lack of association persisted in sensitivity analyses (Figure 2) , and there was no evidence of directional pleiotropy (MR-Egger analysis: all P≥0.19). Our power calculation showed that we had 100% power to detect an OR of 0.9 or lower for all ischemic stroke.
Discussion
This study provides no support that higher S-25OHD concentrations within the normal range are causally associated with ischemic stroke or its subtypes.
A strength of this MR study is that potential confounding and reverse causality, which can bias the findings from conventional observational studies, were reduced by the use of genetic variants as proxy measures for S-25OHD concentrations. Moreover, we were able to investigate the effect of life-long higher S-25OHD concentrations on ischemic stroke because genotype is fixed at conception. Another strength is that we could evaluate the associations of S-25OHD concentrations with subtypes of ischemic stroke. Finally, the large number of cases of ischemic stroke and the use of multiple independent SNPs explaining a relatively large proportion of the variance in S-25OHD concentrations provided high statistical power, which increased the possibility to detect a weak association. A potential limitation of any MR study is pleiotropy, which occurs when a genetic variant affects >1 phenotype. We conducted sensitivity analyses to explore and account for pleiotropy. Our findings were consistent in these analyses, suggesting that pleiotropy does not explain the absence of association between S-25OHD concentrations and ischemic stroke. Another limitation is that we could not investigate potential threshold effects of S-25OHD on ischemic stroke, for example, at either low or high extremes in S-25OHD. We, therefore, cannot rule out that we may have overlooked an association if only rare variants of vitamin D deficiency influences ischemic stroke risk.
In summary, this MR study provides no support that higher S-25OHD concentrations are causally associated with any ischemic stroke subtype. Thus, vitamin D supplementation will unlikely reduce the risk of ischemic stroke in the general population. 
